Calidi Biotherapeutics will host a live investor webinar on April 24, 2025, at 4:15 p.m. ET, featuring newly appointed Chief Medical Officer Dr. Guy Travis Clifton. The event will provide insights into the company's emerging cancer immunotherapy technologies, focusing on its innovative stem cell-based delivery platforms for oncolytic virus therapies.
The webinar will spotlight three key programs in Calidi's pipeline: CLD-201, an FDA-cleared therapy advancing toward trials for solid tumors; CLD-400, targeting metastatic and lung cancer; and CLD-101, designed for high-grade gliomas. These platforms represent a novel approach to cancer treatment, utilizing potent allogeneic stem cells capable of carrying oncolytic viruses.
The company's unique technology aims to enhance the immune system's ability to combat cancer by protecting, amplifying, and potentiating oncolytic viruses. This approach could potentially improve treatment efficacy and patient safety across multiple oncology indications.
By developing off-the-shelf, universal cell-based delivery platforms, Calidi Biotherapeutics is positioning itself at the forefront of innovative cancer treatment strategies. The preclinical virotherapies are specifically designed to target disseminated solid tumors, offering a potential dual approach to treating and potentially preventing metastatic disease.
Following the presentation, a live question-and-answer session will provide investors and interested parties an opportunity to gain deeper insights into the company's cutting-edge cancer immunotherapy research and development efforts.
